查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1224527

美國癌症活檢市場規模、份額和趨勢分析報告：按類型（細針穿刺、核心、手術、皮膚活檢/穿刺活檢）、應用、站點、細分市場預測 2023-2030 年

U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 155 Pages | 商品交期: 2-10個工作天內

價格

美國癌症活檢市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告預測，從 2023 年到 2030 年，美國癌症活檢市場將以 11.12% 的複合年增長率增長，到 2030 年將達到 201.8 億美元。 美國癌症活檢市場的增長歸因於越來越多地採用基於多參數磁共振成像的活檢以及圖像引導穿刺活檢在精準醫學應用中的日益普及。

液體活檢行業預計在未來幾年呈指數級增長，參與生物製藥製造和基因組數據分析的公司不斷增加投資和戰略舉措，預計將發揮核心作用。事實一直如此。 2022 年 4 月，Sekai-Brain 投資 Craif 開發一種用於早期檢測癌症的新型非侵入性液體尿液活檢。

此外，液體活檢的出現、活檢臨床實踐的增加以及遺傳性癌症疾病質量和支付的進步是預計在未來幾年推動市場增長的因素。 癌症患病率上升和老年人口增加也有望推動市場增長。

此外，基於血液的多發性癌症早期檢測 (MCED) 技術的出現有望在預測期內提供有利可圖的機會。 MCED 代表了未來癌症診斷和治療方式的範式轉變。 MCED 帶來的巨大希望是，它將使臨床醫生能夠從篩查少數癌症轉移到篩查大量癌症。

GRAIL 和 Exact Sciences 等公司正在開發 MCED 測試。 此外，美國國家癌症研究所 (NCI) 正在考慮研究和評估 MCED 測試的方法。 NCI 目前正在為 MCED 測試設計臨床試驗和其他研究機會，並且最近向測試開發人員發出了關於他們參與研究計劃的意願的信息請求。

美國癌症活檢市場的主要參與者已採取多項戰略舉措來加強其市場佔有率。 市場進入者的主要舉措包括併購、合作與夥伴關係、地域擴張和新產品發布。 例如，2022 年 4 月，Medtronic開始與 GE Healthcare 合作，以滿足日益增長的門診護理需求。 在此計劃下，客戶將可以獲得金融解決方案、豐富的產品組合和卓越的服務。

美國癌症活檢市場報告要點

由於它是一種確定不確定組織狀況的有效且快速的測試，因此細針抽吸將在 2022 年主導市場

由於對候選新藥開發的需求不斷增長，預計在預測期內，製藥和生物製藥的發現和開發板塊將以最快的速度增長

乳腺癌患病率上升將使乳腺癌細分市場成為 2022 年美國癌症活檢市場創收最高的細分市場

由於政府採取預防措施阻止疾病進展，北美將在 2022 年主導美國癌症活檢市場

內容

第一章調查方法及範圍

  • 調查方法
  • 調查假設
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
      • 初步調查
    • 初步調查的詳細信息
  • 信息或數據分析
    • 數據分析模型
      • 最終用途景觀評估
      • 市場來源評估
      • 腫瘤診斷：市場競爭分析
  • 市場製定和驗證
  • 模型詳細信息
    • 商品流分析
      • 方法 1：商品流方法
      • 方法 2：使用自下而上的方法逐個國家/地區進行市場估算
  • 美國市場：CAGR 計算
  • 二級信息列表
  • 主要信息列表
  • 目的

第 2 章執行摘要

  • 市場展望

第 3 章市場變量、趨勢和範圍

  • 美國和國際癌症醫療旅遊
  • 市場驅動因素分析
    • 液體活檢的出現
    • 將新的腫瘤學診斷方法從實驗台轉移到臨床
    • 提高癌症基因檢測的質量和費用
  • 市場製約因素分析
    • 與活檢程序相關的風險
    • 技術和臨床挑戰
  • 市場機會分析
    • 活檢在腫瘤學伴隨診斷中的重要作用
    • 轉化研究中對活組織檢查的需求不斷增加
  • 市場威脅分析
    • 與重複活檢程序相關的風險

第四章營商環境分析

  • SWOT 分析；按因素（政治和法律、經濟、技術）
  • 波特的五力分析

第五章供應鏈分析

  • 樣品採集（生物樣本庫中心列表）
  • 樣品處理（供應商列表）

第六章成本/價格分析

  • 活檢費用
    • 根據指示
      • 美國醫療保險未涵蓋的患者的典型活檢費用
    • 按類型和方法
  • 影響成本的主要因素
  • 癌症管理的成本
    • 癌症治療藥物和診斷的價格分析
    • 美國在癌症方面的支出（按支付來源）

第 7 章報銷和監管分析

  • 監管框架：美國癌症活檢市場
  • 報銷框架：美國癌症活檢市場

第 8 章問題/約束/並發症分析

  • 問題/制約因素/並發症分析
    • 按地區（器官）
    • 通過方法

第9章癌症活檢產品製造商

第10章類型業務分析

  • 美國癌症活檢市場：類型變異分析
  • 美國癌症活檢市場：活檢類型比較分析
  • 細針穿刺
  • 穿刺活檢 (CNB)
  • 癌症手術活檢
  • 皮膚活檢/穿刺活檢
  • 其他

第11章站點（器官）業務分析

  • 癌症活檢市場：部位（器官）變異分析
  • 胸部
  • 甲狀腺
  • 子宮和子宮頸
  • 肺
  • 前列腺
  • 膀胱
  • 腎臟
  • 肝臟
  • 胰腺
  • 其他網站

第12章應用（原因）業務分析

  • 美國癌症活檢市場：提交（原因）變異分析
  • 篩查和監測
  • 診斷
  • 研究和轉化研究
  • 醫藥和生物製藥的發現和開發

第13章區域業務分析

  • 美國癌症活檢市場：區域差異分析
  • 美國

第14章競爭格局

  • 市場參與分類
  • 戰略框架
  • 供應商情況
    • 主要分銷商和渠道合作夥伴列表
    • 主要客戶
      • 主要客戶名單
    • 上市公司
      • 上市公司名單
    • 私人公司
      • 主要私營公司名單
    • 新興玩家
      • 主要初創企業名單
  • 對主要交易和戰略聯盟的分析
    • 併購
    • 合作與夥伴關係
    • 新產品發布
  • 主要參與者的市場影響分析
    • 安索夫矩陣
    • 公司/競爭對手分類（一級和二級市場進入者）

第十五章公司簡介

  • 公司簡介
    • Bd（Becton, Dickinson And Company）
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Izi Medical Products
      • 公司概況
      • 產品基準
      • 戰略舉措
    • Johnson &Johnson Services, Inc.
      • 公司概況
      • Depuy Synthes
      • 公司概況
      • Ethicon, Inc.
      • 公司概況
      • 財務業績
      • 產品基準
    • Argon Medical
      • 公司概況
      • 產品基準
      • 戰略舉措
      • Cook
      • 公司概況
      • 產品基準
    • Spectra Medical Devices, Inc.
      • 公司概況
      • 產品基準
    • Medtronic
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Boston Scientific Corporation
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
    • Conmed Corporation
      • 公司概況
      • 財務業績
      • 產品基準
    • Inrad, Inc.
      • 公司概況
      • 產品基準
    • Thermo Fisher Scientific, Inc.
      • 公司概況
      • 財務業績
      • 產品基準
      • 戰略舉措
Product Code: GVR-4-68039-467-3

U.S. Cancer Biopsy Market Growth & Trends:

The U.S. cancer biopsy market is expected to reach USD 20.18 billion by 2030, registering a CAGR of 11.12% from 2023 to 2030 according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.

The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.

Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.

Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.

Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.

Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.

U.S. Cancer Biopsy Market Report Highlights:

  • Fine-needle aspiration segment held a dominant share in 2022 owing to the effective and quick test for determining the status of uncertain tissue
  • Pharma & biopharma discovery & development segment is projected to grow at the fastest rate during the forecast period owing to the increasing demand for developing novel drug candidates
  • Breast cancer segment is the highest revenue-generating segment in the U.S. cancer biopsy market in 2022 owing to the increasing prevalence of breast cancer
  • North America dominated the U.S. cancer biopsy market in 2022, which is attributed to preventive measures undertaken by the governments to stop the progression of diseases

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Research Assumptions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
      • 1.4.3.1 Primary Research
    • 1.4.4 Details Of Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
      • 1.5.1.1 End-Use Landscape Assessment
      • 1.5.1.2 Market Origin Assessment
      • 1.5.1.3 Oncology Diagnosis: Market Competition Analysis
  • 1.6 Market Formulation And Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
      • 1.7.1.1 Approach 1: Commodity Flow Approach
      • 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.8 U.S. Market: CAGR Calculation
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
    • 1.11.3 Objective 3
    • 1.11.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook

Chapter 3 Market Variables, Trends, and Scope

  • 3.1 Cancer Medical Tourism Within & Outside the U.S.
  • 3.2 Market Driver Analysis
    • 3.2.1 Advent Of Liquid Biopsy
    • 3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
    • 3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
  • 3.3 Market Restraint Analysis
    • 3.3.1 Risks Associated With Biopsy Procedures
    • 3.3.2 Technical And Clinical Challenges
  • 3.4 Market Opportunity Analysis
    • 3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
    • 3.4.2 Increase In The Demand For Biopsies In Translational Research
  • 3.5 Market Threat Analysis
    • 3.5.1 Risk Associated With Repeat Biopsy Procedures

Chapter 4 Business Environment Analysis

  • 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
  • 4.2 Porter's Five Forces Analysis

Chapter 5 Supply Chain Analysis

  • 5.1 Sample Collection (List of Biobanks/Center)
  • 5.2 Sample Processing (List of Vendors)

Chapter 6 Cost/Pricing Analysis

  • 6.1 Biopsy Cost
    • 6.1.1 By Indication
      • 6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
    • 6.1.2 By Type/Method
  • 6.2 Key Factors Influencing The Cost
  • 6.3 Costs Of Cancer Management
    • 6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
    • 6.3.2 U.S. Expenditures For Cancer By Source Of Payment
      • 6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018

Chapter 7 Reimbursement And Regulatory Analysis

  • 7.1 Regulatory Framework: U.S. Cancer Biopsy Market
  • 7.2 Reimbursement Framework: U.S. Cancer Biopsy Market

Chapter 8 Challenges/Restraints/Complications Analysis

  • 8.1 Challenges/Restraints/Complications Analysis
    • 8.1.1 By Site (Organ)
    • 8.1.2 By Method

Chapter 9 Cancer Biopsy Product Manufacturers

Chapter 10 Type Business Analysis

  • 10.1 U.S. Cancer Biopsy Market: Type Movement Analysis
  • 10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type
  • 10.3 Fine Needle Aspiration
  • 10.4 Core Needle Biopsy (CNB)
    • 10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.5 Cancer Surgical Biopsy
    • 10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.6 Skin Biopsy/Punch Biopsy
    • 10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
      • 10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)
      • 10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)
  • 10.7 Others
    • 10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)
      • 10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
      • 10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Chapter 11 Site (Organ) Business Analysis

  • 11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis
  • 11.2 Breast
    • 11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)
  • 11.3 Thyroid
    • 11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)
  • 11.4 Uterus & Cervix
    • 11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)
  • 11.5 Lung
    • 11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)
  • 11.6 Prostate
    • 11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)
  • 11.7 Bladder
    • 11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)
  • 11.8 Kidney
    • 11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)
  • 11.9 Liver
    • 11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)
  • 11.10 Pancreas
    • 11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)
  • 11.11 Other Sites
    • 11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)

Chapter 12 Application (Cause) Business Analysis

  • 12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis
  • 12.2 Screening & Monitoring
    • 12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)
  • 12.3 Diagnostics
    • 12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)
  • 12.4 Investigational & Translational Research
    • 12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)
  • 12.5 Pharma & Biopharma Discovery & Development
    • 12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)

Chapter 13 Regional Business Analysis

  • 13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis
  • 13.2 U.S.
    • 13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)

Chapter 14 Competitive Landscape

  • 14.1 Market Participation Categorization
  • 14.2 Strategy Framework
  • 14.3 Vendor Landscape
    • 14.3.1 List Of Key Distributors And Channel Partners
    • 14.3.2 Key Customers
      • 14.3.2.1 List Of Key Customers
    • 14.3.3 Public Companies
      • 14.3.3.1 List Of Public Companies
    • 14.3.4 Private Companies
      • 14.3.4.1 List Of Key Private Companies
    • 14.3.5 Emerging Players
      • 14.3.5.1 List Of Key Emerging Companies
  • 14.4 Major Deals And Strategic Alliances Analysis
    • 14.4.1 Mergers And Acquisitions
    • 14.4.2 Collaborations And Partnerships
    • 14.4.3 New Product Launch
  • 14.5 Market Impact Analysis By Key Participants
    • 14.5.1 Ansoff Matrix
    • 14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)

Chapter 15 Company Profiles

  • 15.1 Company Profiles
    • 15.1.1 Bd (Becton, Dickinson And Company)
      • 15.1.1.1 Company Overview
      • 15.1.1.2 Financial Performance
      • 15.1.1.3 Product Benchmarking
      • 15.1.1.4 Strategic Initiatives
    • 15.1.2 Izi Medical Products
      • 15.1.2.1 Company Overview
      • 15.1.2.2 Product Benchmarking
      • 15.1.2.3 Strategic Initiatives
    • 15.1.3 Johnson & Johnson Services, Inc.
      • 15.1.3.1 Company Overview
      • 15.1.3.2 Depuy Synthes
      • 15.1.3.2.1 Company Overview
      • 15.1.3.3 Ethicon, Inc.
      • 15.1.3.3.1 Company Overview
      • 15.1.3.4 Financial Performance
      • 15.1.3.5 Product Benchmarking
    • 15.1.4 Argon Medical
      • 15.1.4.1 Company Overview
      • 15.1.4.2 Product Benchmarking
      • 15.1.4.3 Cook
      • 15.1.4.4 Company Overview
      • 15.1.4.5 Product Benchmarking
    • 15.1.5 Spectra Medical Devices, Inc.
      • 15.1.5.1 Company Overview
      • 15.1.5.2 Product Benchmarking
    • 15.1.6 Medtronic
      • 15.1.6.1 Company Overview
      • 15.1.6.2 Financial Performance
      • 15.1.6.3 Product Benchmarking
      • 15.1.6.4 Strategic Initiatives
    • 15.1.7 Boston Scientific Corporation
      • 15.1.7.1 Company Overview
      • 15.1.7.2 Financial Performance
      • 15.1.7.3 Product Benchmarking
      • 15.1.7.4 Strategic Initiatives
    • 15.1.8 Conmed Corporation
      • 15.1.8.1 Company Overview
      • 15.1.8.2 Financial Performance
      • 15.1.8.3 Product Benchmarking
    • 15.1.9 Inrad, Inc.
      • 15.1.9.1 Company Overview
      • 15.1.9.2 Product Benchmarking
    • 15.1.10 Thermo Fisher Scientific, Inc.
      • 15.1.10.1 Company Overview
      • 15.1.10.2 Financial Performance
      • 15.1.10.3 Product Benchmarking
      • 15.1.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 Reasons for the popularity of oncology tourism in some countries
  • Table 3 Common types of oncology tourism treatments
  • Table 4 Liquid biopsy developing or commercializing companies
  • Table 5 Average pricing analysis: Biopsy to indication
  • Table 6 Average pricing analysis: Biopsy to indication
  • Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018
  • Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)
  • Table 9 Types of insurance coverage
  • Table 10 Policy structure types issued by private payers and Medicare
  • Table 11 Coverage policies for ctDNA
  • Table 12 CPT codes for minimally invasive prostate procedures
  • Table 13 CPT codes for office visits-new & established patient
  • Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis
  • Table 15 Comparative analysis of traditional and liquid liver biopsies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 End-use landscape: Cancer biopsy product penetration
  • Fig. 5 Cancer biopsy: Market origin/parent market assessment
  • Fig. 6 Market competition analysis: Early diagnosis industry sector
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. cancer biopsy market outlook (2022)
  • Fig. 9 U.S. cancer biopsy market driver impact
  • Fig. 10 External factors driving the demand for cancer biopsy
  • Fig. 11 U.S. cancer biopsy market restraint impact
  • Fig. 12 SWOT analysis
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Key driving factors of biopsy costs
  • Fig. 15 U.S. expenditures for cancer by payment source, 2018
  • Fig. 16 National cancer costs projected to increase drastically by 2030, in USD Billion
  • Fig. 17 U.S. out-of-pocket expenses 2014 vs. 2018
  • Fig. 18 U.S. cancer management expenditure
  • Fig. 19 U.S. cancer biopsy market: Type outlook and key takeaways
  • Fig. 20 U.S. cancer biopsy market: Type movement analysis
  • Fig. 21 Tissue biopsy vs liquid biopsy: Comparative analysis
  • Fig. 22 U.S. cancer core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. cancer core needle biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. cancer core needle biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. cancer surgical biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. cancer surgical biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. cancer surgical biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. skin biopsy/punch cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U. S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. cancer liquid biopsy market estimates and forecasts for other types, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. other types of cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. other types of cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
  • Fig. 37 Cancer biopsy market: Site (Organ) outlook and key takeaways
  • Fig. 38 Cancer biopsy market: Site (Organ) movement analysis
  • Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. cancer biopsy market: Application (Cause) outlook and key takeaways
  • Fig. 50 U.S. cancer biopsy market: Application (Cause) movement analysis
  • Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. cancer biopsy market, 2018 - 2030 (USD million)
  • Fig. 56 Participant categorization - U.S. cancer biopsy market
  • Fig. 57 Strategy framework - U.S. cancer biopsy market
  • Fig. 58 Ansoff matrix
  • Fig. 59 Competition categorization